The research paper discusses the main aspects of Section 3(d) ofthe Indian Patent Act 1970 with respect to the Indianpharmaceutical industry. Three cases viz. the Novartis Glivec,Pfizer's Sutent and GSK's Tykerb have been discussed thatexplicitly...
Recently there has been a perception, especially amongst the foreign multinational pharmaceutical companies that Indian Patent Act doesn't provide the adequate protection to inventions. Their belief basically flows from the fact that while inventions are patentable in developed jurisdictions like USA, ...
Section 3 of the Patent Act 1970Section 3 of the Patent Act 1970, talks about the invention which is not patentable, it means non patentable subject matter or it means even if something has bePhulwari, GajendraSocial Science Electronic Publishing...
The authors propose an amendment in Section 3(d) of the Indian Patent Act, 1970 and some steps that the patent office could take to promote nanotechnology patenting in India and in turn aid the nanotechnology industry growth in India.Nandekar, Ujwal Prabhakar...
Controvery of Section 3(D) of the Indian Patent ActWe shall be discussing the amendment which the Indian government made to their Intellectual property laws in 2005 and the effects it is having to the rest of thDaureeawo, RaheelSocial Science Electronic Publishing...
Section 8 of the Indian Patent Act: Neither an Idle Menace nor A Mere FormalityVarshney, Swati
Sowing the Seeds of Change? Patent Policy and Section 3(D) of the Indian Patent Act, 1970PatentSection 3(dIndiaNovartisGlivecGleevecnew form of a known substancePolymorphPharmaceutical PatentsIPABThis article makes an attempt to view the interpretation of Section 3(d) by the Intellectual Property...
Analysis of section 3(D) of patent amendment act, 2005 and its impact on pharmaceutical industry with especial reference to novartis caseRajpurohit, Govind SinghKumar, Kailash
Indian patentsystem had advanced by various amendment(s) including Section 3 (d) of the Act (Patent Act 1970). Aim: The study is aimed essential to provide evidence in protection of desirable patent and to understand implications of Section 3 (d) in terms of protecting creativity, ...
Diamond v Chakrabarty, 447 US 308, 100 S Ct at 2207; Novartis AG & Anr v Union of India & Othrs, (2007) 4 MLJ 1153, 20; Basheer Shamnad and Reddy Prashant, The `Efficacy' of Indian patent law: Ironing out the creases in Section 3(d), Script-ed, 5 (2) (2008) 12.Basheer S...